bivamelagon
bivamelagon: sourced relationships with 1 company · 2 clinical trials tracked.
bivamelagon evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could bivamelagon → RYTM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | Phase 2 |
Clinical Trial Registry Records (2)
A Long-Term, Open-Label Extension Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Primary endpoint: Safety and tolerability of bivamelagon as assessed by the number and frequency of AEs
A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension
Primary endpoint: Mean percentage change in BMI
Frequently asked questions
Which companies have sourced relationships with bivamelagon?
bivamelagon has dated SEC/FDA relationship records for RHYTHM PHARMACEUTICALS, INC..
How many clinical trials involve bivamelagon?
BioSniper tracks 2 clinical trials involving bivamelagon.